Abstract: An additive for a water-based wood stain includes a polymeric particle including a polymer that includes a repeating unit formed from a compound having the formula X-L1-A, wherein X is a substituted or unsubstituted (C2-C8)alkenyl containing one or more carbon-carbon double bonds, L1 is a bond, —C(O)—O—, —O—C(O)—, or a substituted or unsubstituted (C1-C10)alkylene interrupted by 0, 1, 2, or 3 heteroatoms chosen from O and NR1 wherein R1 is —H or (C1-C5)alkyl, and A is —H, substituted or unsubstituted (C1-C20)hydrocarbyl, or substituted or unsubstituted phenyl. The polymeric particle has a particle size in solution of 10 nm to 2000 nm.

Abstract: Aspects of the subject disclosure may include, for example, obtaining first magnetic resonance imaging (MRI) data of a subject, wherein the first MRI data is obtained during a first scan of a subject, wherein the first scan has a first diffusion sampling time, and wherein the first diffusion sampling time is selected in order to facilitate use of the first MRI data to determine a first Intravoxel Incoherent Motion (IVIM) effective diffusion coefficient in a Stationary Random Flow (SRF) regime; obtaining second MRI data of the subject, wherein the second MRI data is obtained during a second scan of the subject, wherein the second scan has a second diffusion sampling time, wherein the second diffusion sampling time is longer than the first diffusion sampling time, and wherein the second diffusion sampling time is selected in order to facilitate use of the second MRI data to determine a second IVIM effective diffusion coefficient in a pseudodiffusion regime; determining a blood velocity value based upon the firs

Abstract: Aspects of the subject disclosure may include, for example, obtaining first magnetic resonance imaging (MRI) data of a subject, wherein the first MRI data is obtained during a first scan of a subject, wherein the first scan has a first diffusion sampling time, and wherein the first diffusion sampling time is selected in order to facilitate use of the first MRI data to determine a first Intravoxel Incoherent Motion (IVIM) effective diffusion coefficient in a Stationary Random Flow (SRF) regime; obtaining second MRI data of the subject, wherein the second MRI data is obtained during a second scan of the subject, wherein the second scan has a second diffusion sampling time, wherein the second diffusion sampling time is longer than the first diffusion sampling time, and wherein the second diffusion sampling time is selected in order to facilitate use of the second MRI data to determine a second IVIM effective diffusion coefficient in a pseudodiffusion regime; determining a blood velocity value based upon the firs

Abstract: A dynamic system for generating electricity from a changing magnetic field includes solenoids routed on a single iron core, switches, and diodes. A first solenoid and a second solenoid are stationary electromagnet coils opposably routed on the iron core. A third solenoid is a stationary electric current induction coil. The first and second solenoids induce opposing magnetic fields on receiving an initial magnetizing current from a solar cell. One of the switches includes a switching system that alternately connects at least one switching node, for example, via one or more pivot joints, to one of at least two contact nodes to form a closed electric system with the first solenoid or the second solenoid, the solar cell, and a load and to change the induced magnetic field in the first solenoid or the second solenoid. The changing magnetic field induces an electric current in the third solenoid.

Abstract: The systems and methods described herein relate to impairment assessments that may use frequent baseline examinations of users to generate a performance threshold that allows more reliable impairment tests to be administered at accident sites. Assessment test results may also be forwarded to other parties to indicate when a user should seek medical attention.

Abstract: Osteogenic proteins are delivered via an injectable solid rod or hardenable paste. The formulation comprises a calcium phosphate material, an osteogenic protein, and optional additives and active ingredients such as a bone resorption inhibitor. Methods of making injectable pharmaceutical compositions and methods of using the osteogenic compositions to treat bone defects are also disclosed.

Abstract: A composition for delivery of osteogenic proteins is disclosed. The composition comprises an osteogenic protein, a calcium phosphate material as a carrier, and an effective amount of an effervescent agent. Methods of making the compositions and methods of using the osteogenic compositions to treat osteoporotic and/or osteopenic bone are also disclosed.

Abstract: Osteogenic proteins are delivered via an injectable solid rod or hardenable paste. The formulation comprises a calcium phosphate material, an osteogenic protein, and optional additives and active ingredients such as a bone resorption inhibitor. Methods of making injectable pharmaceutical compositions and methods of using the osteogenic compositions to treat bone defects are also disclosed.

Abstract: Osteogenic proteins are delivered via an injectable solid rod or hardenable paste. The formulation comprises a calcium phosphate material, an osteogenic protein, and optional additives and active ingredients such as a bone resorption inhibitor. Methods of making injectable pharmaceutical compositions and methods of using the osteogenic compositions to treat bone defects are also disclosed.

Abstract: A composition for delivery of osteogenic proteins is disclosed. The composition comprises an osteogenic protein, a calcium phosphate material as a carrier, and an effective amount of an effervescent agent. Methods of making the compositions and methods of using the osteogenic compositions to treat osteoporotic and/or osteopenic bone are also disclosed.

Abstract: A composition for delivery of osteogenic proteins is disclosed. The composition comprises an osteogenic protein, a calcium phosphate material as a carrier, and an effective amount of an effervescent agent. Methods of making the compositions and methods of using the osteogenic compositions to treat osteoporotic and/or osteopenic bone are also disclosed.

Abstract: An injectable formulation is disclosed for delivery of osteogenic proteins. The formulation comprises a pharmaceutically acceptable admixture of an osteogenic protein; and formulations comprising osteogenic protein, hyaluronic acid derivatives and tricalcium phosphate are also disclosed. Methods for formulating porous injectable gels and pastes from hyaluronic acid are also disclosed.

Abstract: A composition for delivery of osteogenic proteins is disclosed. The composition comprises an osteogenic protein, a calcium phosphate material as a carrier, and an effective amount of an effervescent agent. Methods of making the compositions and methods of using the osteogenic compositions to treat osteoporotic and/or osteopenic bone are also disclosed.

Abstract: An injectable formulation is disclosed for delivery of osteogenic proteins. The formulation comprises a pharmaceutically acceptable admixture of an osteogenic protein; and formulations comprising osteogenic protein, hyaluronic acid derivatives and tricalcium phosphate are also disclosed. Methods for formulating porous injectable gels and pastes from hyaluronic acid are also disclosed.

Abstract: An injectable formulation is disclosed for delivery of osteogenic proteins. The formulation comprises a pharmaceutically acceptable admixture of an osteogenic protein; and formulations comprising osteogenic protein, hyaluronic acid derivatives and tricalcium phosphate are also disclosed. Methods for formulating porous injectable gels and pastes from hyaluronic acid are also disclosed.

Abstract: An injectable or implantable rod-shaped formulation is disclosed for delivery of osteogenic proteins. The formulation comprises hyaluronic acid derivatives and osteogenic proteins, and optional excipients and active ingredients such as a bone resorption inhibitor. Methods of making injectable rod-shaped pharmaceutical compositions and methods of using the osteogenic compositions to treat osteoporotic and/or osteopenic bone are also disclosed.

Abstract: Osteogenic proteins are delivered via an injectable solid rod or hardenable paste. The formulation comprises a calcium phosphate material, an osteogenic protein, and optional additives and active ingredients such as a bone resorption inhibitor. Methods of making injectable pharmaceutical compositions and methods of using the osteogenic compositions to treat bone defects are also disclosed.

Abstract: A device is provided containing cells or tissue distributed on a filamentous cell-supporting matrix which is encapsulated by a semi-permeable membrane which can be immunoisolatory. The matrix may be formed of a plurality of monofilaments twisted into yarn that is in non-woven strands, or of the monofilaments or yarn woven into a mesh. Configurations of the matrix include a hollow cylinder, tube, solid cylinder or cord. A coating of extracellular matrix molecules may be on the matrix, or the matrix may be treated with plasma irradiation to enhance cell adhesion. The device can be made by inserting the matrix in a hollow membrane tube, injecting cells or tissue into the tube and sealing ends of the tube. The device is particularly useful for implantation into a mammalian host to provide therapy resulting from a biologically active molecule produced by the cells and tissue.

Abstract: A device is prepared having cells or tissue attached to a non-degradable filamentous matrix surrounded by a semi-permeable membrane. The matrix is preferably formed of a plurality of monofilaments twisted into a yarn or woven into a mesh, and can be in the form of a cylinder. When implanting the device, the semi-permeable membrane is preferably immunolsolatory, and the cells or tissue may produce a biologically active molecule to provide therapy. To enhance cell or tissue adhesion, the matrix is coated with extracellular matrix molecules or treated to provide a surface charge. The device can be made by inserting the matrix into a capsule formed of the semi-permeable membrane, distributing the cells or tissue on the matrix through an opening of the capsule, and sealing the opening of the capsule.

Abstract: This invention is directed to methods of manufacturing implantable biocompatible cell encapsulation devices, wherein the cell encapsulation devices have a jacket made of a permeable, biocompatible material that is loaded with a core made of a reticulate foam scaffold having interconnected pores, with cells that are dispersed in the interconnected pores.